TABLE 3.

Participant's UGT1A1 genotype, functionality score, race, ethnicity, and plasma raltegravir-glucuronide/raltegravir geometric mean ratio by study arm

Participant	Race	Hispanic	Genotypea	Scoreb	Plasma raltegravir- glucuronide/ raltegravir GMR in armc
					A	B
1	Caucasian	No	*1/*1	0	1.00	0.45
2	Caucasian	Yes	*1/*1	0	0.97	0.68
3	Caucasian	No	*1/*28	−1	0.81	0.53
4	Caucasian	No	*1/*28	−1	1.99	1.04
5	Asian	No	*1/*28	−1	1.09	0.60
6	Caucasian	No	*1/*1	0	0.98	0.25
7	Asian	No	*1/*1	0	2.16	0.54
8	Caucasian	Yes	*1/*1	0
9	Caucasian	No	*28/*28	−2	0.47	0.27
10	Caucasian	No	*1/*28	−1	1.50	0.62
11	Asian	No	*1/*1	0	1.25	0.51
12	Caucasian	No	*1/*1	0	1.76	0.42
13	Asian	No	*1/*81	0	0.51	0.33
14	Asian	No	*1/*81	0	0.70	0.52
15	African American	No	*1/*28	−1	1.04	0.40
16	Caucasian	Yes	*1/*X	−1	1.02	0.52
17	African American	No	*1/*28	−1	0.77	0.43
18	Caucasian	No	*1/*28	−1	1.02	0.45
19	African American	No	*1/*28	−1	1.00	0.69
20	Caucasian	No	*1/*1	0	0.93	0.31
Avg					1.02†	0.47†

^a*1, reference sequence A(TA)₆TAA; *28, A(TA)₇TAA; *81, g.-64G>C; *X A(TA)₉TAA.

^bScore, UGT1A1 score as described in Materials and Methods.

^cArm A, raltegravir alone; arm B, raltegravir with atazanavir. Participant 8 did not complete the pharmacokinetic study but was genotyped. †, P < 0.0001.